Evidence map›Paper›PMID 28884609›Full record

ArticleClinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis2018

Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome.

Daniel Navarro-Carpentieri, Maria Del Carmen Castillo-Hernandez, Karim Majluf-Cruz, Guillermo Espejo-Godinez, Paola Carmona-Olvera, Manuel Moreno-Hernandez, Yolanda Lugo-García, Jesús Hernandez-Juarez, Luis Loarca-Piña, Irma Isordia-Salas and 1 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 13 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Daniel Navarro-Carpentieri1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Maria Del Carmen Castillo-Hernandez2 Laboratorio de Farmacologia Cardiovascular, Seccion de Estudios de Posgrado, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico City, Mexico.
Karim Majluf-Cruz1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Guillermo Espejo-Godinez1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Paola Carmona-Olvera1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Manuel Moreno-Hernandez1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Yolanda Lugo-García4 Servicio de Hematologia, Hospital General Regional Carlos MacGregor Sanchez Navarro, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Jesús Hernandez-Juarez1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Luis Loarca-Piña3 Hospital Angeles del Pedregal, Queretaro, Queretaro, Mexico.
Irma Isordia-Salas1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Abraham Majluf-Cruz1 Unidad de Investigacion Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Mexico City, Mexico.
Mexican Social Security Institute · MXHospital Angeles Pedregal · MXInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are classical risk factors associated with arterial thrombosis (AT) or venous thromboembolic disease (VTD). However, less is known about these risk factors and AT or VTD episodes in patients with antiphospholipid syndrome (APS). Our aim was to elucidate whether APS-related thrombotic episodes are associated with the same risk factors as the non-APS population. We gathered demographics, medical history, complications, and causes of death associated with the risk factors for AT or VTD in patients with APS. We analyzed 677 thrombotic events in 386 patients. Type 2 diabetes mellitus and grade 3 obesity were associated with VTD instead of AT. There were no significant differences between the groups for almost all laboratory tests analyzed, although lupus anticoagulant was significantly higher in the VTD group. We suggest that thrombosis in APS is due to the APS itself and that the risks factors for AT or VTD do not have a main role. Our findings may have an ethnical background. Therefore, it may be difficult to elaborate predictive thrombotic clinical scores applicable to patients with different ethnical background.

Indexed as

AdultAntiphospholipid SyndromeCoronary ThrombosisDiabetes Mellitus, Type 2FemaleHumansLupus Coagulation InhibitorMaleMiddle AgedObesityRisk FactorsThrombosisVenous ThrombosisLupus Coagulation Inhibitorantiphospholipid syndromeantiphospolipid antibodiesarterial thrombosisthromboembolic risk factorsvenous thrombosis

Identifiers

PMID28884609
PMCPMC6714872
OpenAlexW2753480442

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.